A jury in the US District Court of Eastern District of Texas decided on 8 April that the sale in the US of Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan; DS-8201) infringes Seagen Inc. ’s US patent 10,808,039.
Daiichi Vows Action As $41.8m Patent Decision Favors Seagen
‘039 Claims Also Now Under Review
A US jury decision in a long-running ADC patent dispute between Seagen and Daiichi Sankyo has found in favor of the US firm. But Daiichi has vowed to challenge the outcome while its motion to question the validity of the original patent on which the case is based has also just been granted, meaning the final impact remains uncertain.
More from Legal & IP
• By
Plus deals involving Incyte/Genesis, Merck & Co./Epitopea, Merck Serono/Asceneuron, Tivic Health/Statera and more.
• By
Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.
• By
Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.
• By
India cracks down on unethical marketing practices, with AbbVie in the eye of a storm for allegedly violating norms. While the action sends the right signal, a wider clean up including in the devices segment, where things may be “more harmful” may not be easy, say some experts.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.